| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1046192944 |
| P356 | DOI | 10.1186/S12885-015-1529-X |
| P932 | PMC publication ID | 4507314 |
| P698 | PubMed publication ID | 26194186 |
| P5875 | ResearchGate publication ID | 281821345 |
| P50 | author | Rebecca KS Wong | Q57618405 |
| Mark Smithers | Q64411484 | ||
| John Zalcberg | Q89468021 | ||
| Gail E Darling | Q96650314 | ||
| Alex Boussioutas | Q46898156 | ||
| P2093 | author name string | John Simes | |
| Florian Lordick | |||
| Val Gebski | |||
| Michael Michael | |||
| Karin Haustermans | |||
| Christoph Schuhmacher | |||
| Carol Swallow | |||
| Danielle Miller | |||
| Trevor Leong | |||
| P2860 | cites work | Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction | Q28215716 |
| Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer | Q29619394 | ||
| The impact of radiotherapy on survival in resectable gastric carcinoma: a meta-analysis of literature data. | Q31133052 | ||
| Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response | Q34570217 | ||
| Survival after radiotherapy in gastric cancer: systematic review and meta-analysis | Q34609710 | ||
| Lymph node metastases of gastric cancer. General pattern in 1931 patients | Q34680739 | ||
| Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma | Q44978576 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chemotherapy | Q974135 |
| chemoradiotherapy | Q5090613 | ||
| phase III clinical trial | Q42824827 | ||
| P304 | page(s) | 532 | |
| P577 | publication date | 2015-07-21 | |
| P1433 | published in | BMC Cancer | Q326300 |
| P1476 | title | TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG). | |
| P478 | volume | 15 |
| Q28088619 | Adjuvant and/or neoadjuvant therapy for gastric cancer? A perspective review |
| Q88443389 | Adjuvant radiochemotherapy in locally advanced gastric cancer : Treatment results and analysis of possible prognostic factors |
| Q26774528 | Advanced gastric cancer: What we know and what we still have to learn |
| Q90318996 | Advancements and challenges in treating advanced gastric cancer in the West |
| Q54465350 | Anti-angiogenesis: disappointment in localised oesophagogastric cancer. |
| Q58737369 | Between evidence and new perspectives on the current state of the multimodal approach to gastric cancer: Is there still a role for radiation therapy? |
| Q58755544 | CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in re |
| Q36967771 | Combination of preoperative platelet/lymphocyte and neutrophil/lymphocyte rates and tumor-related factors to predict lymph node metastasis in patients with gastric cancer |
| Q55400693 | Comparison of perioperative chemotherapy with adjuvant chemoradiotherapy for resectable gastric cancer: findings from a population-based study. |
| Q58804566 | Computed tomography-based radiomics for prediction of neoadjuvant chemotherapy outcomes in locally advanced gastric cancer: A pilot study |
| Q90319007 | Current status of adjuvant chemotherapy for gastric cancer |
| Q38890205 | Current treatment options for esophageal diseases |
| Q38712738 | Evaluation of the American Joint Committee on Cancer 8th edition staging system for gastric cancer patients after preoperative therapy |
| Q39343374 | Gastric adenocarcinoma. |
| Q99622843 | Gastric cancer |
| Q59482283 | Histopathologic Features are more Important Prognostic Factors than Primary Tumour Location in Gastro-oesophageal Adenocarcinoma Treated with Preoperative Chemoradiation and Surgery |
| Q96305347 | IMRT Reduces Acute Toxicity in Patients Treated With Preoperative Chemoradiation for Gastric Cancer |
| Q91793873 | Imaging strategies in the management of gastric cancer: current role and future potential of MRI |
| Q38618861 | Left Gastric Artery Lymph Nodes Should Be Included in D1 Lymph Node Dissection in Gastric Cancer |
| Q34326546 | Medical management of gastric cancer: a 2014 update |
| Q33650849 | Neoadjuvant Chemotherapy and Adjuvant Chemoradiation Therapy in the Treatment of Resected Gastric Adenocarcinoma: A Case Series |
| Q38636439 | Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial |
| Q41202499 | Neoadjuvant treatment of locally advanced esophageal and junctional cancer: the evidence-base, current key questions and clinical trials |
| Q88635050 | Nodal Downstaging in Gastric Cancer Patients: Promising Survival if ypN0 is Achieved |
| Q55359616 | Optimal management of resected gastric cancer. |
| Q36149779 | Outcome of neoadjuvant therapies for cancer of the oesophagus or gastro-oesophageal junction based on a national data registry |
| Q64445698 | Patients unfit for neoadjuvant therapy may still undergo resection of locally advanced esophageal or esophagogastric junctional cancer with acceptable oncological results |
| Q43285072 | Patterns of relapse in patients with localized gastric adenocarcinoma who had surgery with or without adjunctive therapy: costs and effectiveness of surveillance. |
| Q38748376 | Perioperative chemotherapy for resectable gastric cancer - what is the evidence? |
| Q38848598 | Perioperative chemotherapy versus postoperative chemoradiotherapy in patients with resectable gastric/gastroesophageal junction adenocarcinomas: A survival analysis of 5058 patients. |
| Q64916251 | Preoperative chemoradiation therapy induces primary-tumor complete response more frequently than chemotherapy alone in gastric cancer: analyses of the National Cancer Database 2006-2014 using propensity score matching. |
| Q47549613 | Racial disparities in preoperative chemotherapy use in gastric cancer patients in the United States: Analysis of the National Cancer Data Base, 2006-2014. |
| Q64912862 | Recent advances in the management of gastric adenocarcinoma patients. |
| Q90173443 | Recent progress in multidisciplinary treatment for patients with esophageal cancer |
| Q58806085 | Role of lymph node ratio in selection of adjuvant treatment (chemotherapy chemoradiation) in patients with resected gastric cancer |
| Q38888100 | Stage-directed individualized therapy in esophageal cancer |
| Q64929097 | Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT. |
| Q38880523 | TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG. |
| Q64078991 | The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer |
| Q55218646 | The role of neoadjuvant chemoradiotherapy in multimodality treatment of esophageal or gastroesophageal junction cancer. |
| Q41431591 | Treatment of localized gastric and gastroesophageal adenocarcinoma: the role of accurate staging and preoperative therapy. |
| Q38594498 | Updated evidence on adjuvant treatments for gastric cancer |
| Q58107629 | [Adjuvant radiotherapy in the multimodal treatment of resectable gastric cancer-criticism of the conclusions drawn from CRITICS?] |
Search more.